CLINICAL VALUE OF THE MARKERS OF PROLIFERATION AND APOPTOSIS IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA
https://doi.org/10.17650/1726-9776-2014-10-1-10-15
Abstract
Renal cell carcinoma (RCC) is a heterogeneous disease in which the patients survive for months to years. At the present time the prognostic models have no sufficient information or exact prognostic value. Cell proliferation and apoptosis play a key role in cell cycle regulation; and impairment in these processes is commonly detected in different human tumors. The investigation enrolled 76 patients (49 men, 27 women) aged 32 to 73 years (mean age 56 ± 7.6 years) diagnosed with RCC. The follow-up was 8 to 116 months (mean 36.5 months). All the patients underwent nephrectomy; antibodies against р53, Bcl-2, and Ki-67 were investigated by immunohistochemistry. The expression of p53 and none or reduced expression of Bcl-2 are poor prognostic factors and associated with the metastatic potential of a tumor and with low relapse-free survival. High Ki-67 levels are a risk factor for metastases. A combination of p53 expression and high proliferative activity reflects the aggressive potential of a tumor and suggests the high risk of metastases just at the disease diagnosis and early tumor dissemination.
About the Authors
N. A. Gorban
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
S. V. Ivanova
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
O. B. Karyakin
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
A. M. Popov
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
S. A. Varlamov
Altai Territory Oncology Dispensary, Barnaul
Russian Federation
Russian Federation
D. I. Ganov
Altai Territory Oncology Dispensary, Barnaul
Russian Federation
Russian Federation
References
1. Hollingsworth J. M., Miller D. C., Daignault S., Hollenbeck B.K. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 2007;109:1763–8.
2. Cindolo L., Patard J. J., Chiodini P. et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005;104:1362–71.
3. Lam J. S., Shvarts O., Leppert J. T. et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174:466–72.
4. Kattan M. W., Reuter V., Motzer R. J. et al. A postoperative prognostic nomogram foe renal cell carcinoma. J Urol 2001;166:63–7.
5. Москвина Л. В., Андреева Ю. Ю., Мальков П. Г. и др. Клинически значимые морфологические параметры почечноклеточного рака. Онкология 2013;(4):34–9.
6. Алексеев Б. Я., Франк Т. А., Андреева Ю. Ю., Калпинский А. С. Прогностические факторы у больных почечно-клеточным раком и роль онкофага в улучшении выживаемости после хирургического лечения. Онкоурология 2009;(2):7–14.
7. Itoi T., Yamana K., Bilim V. et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 2004 Jan 12;90(1):200–5.PMID:14710230.
8. Шацева Т. А., Мухина М. С. Антиген Ki-67 в оценке опухолевой пролиферации. Его структура и функции. Вопр онкол 2004;50(2):157–64.
9. Чумаков П. М. Функция гена р53: выбор между жизнью и смертью. Биохимия 2000;65(1):34–47.
10. Kankuri M., Sцderstrцm K. O., Pelliniemi T. T. et al. The association ofimmunoreactive p53 and Ki-67 with T-stage,grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res 2006;26(5B):3825–33.
11. Masuda A., Kamai T., Abe H. et al. Is Stat3 and / or p53 mRNA expression a prognostic marker for renal cell carcinoma?Biomed Res 2009;30(3):171–6.
12. Paul L. Crispen, Stephen A. Boorjian,Christine M. Lohse et al. Predicting Disease Progression After Nephrectomy for Localized Renal Cell Carcinoma: The Utility of Prognostic Models and Molecular Biomarkers. Cancer. Author manuscript; available in PMC 2009 November 30. Published in final edited form as. Cancer 2008;113(3):450–60.
13. World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press, 2004.
14. Боровиков В. П., Боровиков И. П. Статистический анализ и обработка данных в среде Windows. М., 1998. 592 с.
15. Klatte T., Seligson D. B., LaRochelle J. et al. Molecular signatures of localized clear cell renal cell carcinoma to predict diseasefree survival after nephrectomy. Canc Epidemiol Biomarkers Prev 2009; 18(3):894–900.
16. Rioux-Leclercq N., Epstein J. I., Bansard J. Y. et al. Clinical significance of cell proliferation, microvessel density, and CD44adhesion molecule expression in renal cell carcinoma. Hum Pathol 2001;32(11): 1209–15.
17. Yildiz E., Gokce G., Kilicarslan H. et al. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor,and microvessel invasion, in renal cell carcinoma. BJU Int 2004;93(7):1087–93.
18. Sakai I., Miyake H., Takenaka A., Fujisawa M. Expression of potential molecular markers in renal cell carcinomaimpact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int 2009;104(7):942–6.
19. Haitel A., Wiener H. G., Baethge U. et al. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin Cancer Res 2000;6(5):1840–4.
20. Uzunlar A. K., Sahin H., Yilmaz F., Ozckinci S. Expression of p53 oncoprotein and bcl-2 in renal cell carcinoma. Saudi Med J 2005;26(1):37–41.
21. Warburton H. E., Brady M., Vlatković N. et al. p53 regulation and function in renal cell carcinoma. Cancer Res 2005;65(15):6498–503.
22. Noon A. P., Vlatkovic N., Polanski R. et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer 2010;116 (4):780–90.
23. Kim H. L., Seligson D., Liu X. et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;173(5):1496–501.
24. Kramer B. A., Gao X., Davis M. et al. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. J Am Coll Surg 2005;201(4):565–70.
25. Meteoglu I., Erdogdu I. H., Meydan N. et al. NF-Kappa B expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res 2008;27:53.
26. Miyake H., Sakai I., Muramaki M. et al. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol 2009; 16(5):465–71.
Review
For citations:
Gorban N.A., Ivanova S.V., Karyakin O.B., Popov A.M., Varlamov S.A., Ganov D.I. CLINICAL VALUE OF THE MARKERS OF PROLIFERATION AND APOPTOSIS IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA. Cancer Urology. 2014;10(1):10-15. (In Russ.) https://doi.org/10.17650/1726-9776-2014-10-1-10-15
Views:
851
Email this article 